ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
95 389,23
-1,87%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. IceCure Medical Ltd (ICCM)

  7. IceCure Medical Ltd (ICCM) Actualités

ICCM

IceCure Medical (ICCM)

IceCure Medical Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ICCM
DateHeureSourceTitreSymboleSociété
16/12/202414h30PR Newswire (US)Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual MeetingNASDAQ:ICCMIceCure Medical Ltd
05/12/202414h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
05/12/202414h30PR Newswire (US)IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study ResultsNASDAQ:ICCMIceCure Medical Ltd
26/11/202414h30PR Newswire (US)IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® CryoablationNASDAQ:ICCMIceCure Medical Ltd
25/11/202414h30PR Newswire (US)IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent OfficeNASDAQ:ICCMIceCure Medical Ltd
20/11/202414h30PR Newswire (US)IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024NASDAQ:ICCMIceCure Medical Ltd
19/11/202414h30PR Newswire (US)IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of HealthNASDAQ:ICCMIceCure Medical Ltd
15/11/202403h38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202416h05Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202413h00PR Newswire (US)FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast CancerNASDAQ:ICCMIceCure Medical Ltd
29/10/202413h30PR Newswire (US)Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from StakeholdersNASDAQ:ICCMIceCure Medical Ltd
21/10/202414h30PR Newswire (US)IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation SystemNASDAQ:ICCMIceCure Medical Ltd
15/10/202422h22Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:ICCMIceCure Medical Ltd
07/10/202414h15PR Newswire (US)IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging ConferenceNASDAQ:ICCMIceCure Medical Ltd
24/09/202414h15PR Newswire (US)IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free RateNASDAQ:ICCMIceCure Medical Ltd
16/09/202414h00PR Newswire (US)Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft TissuesNASDAQ:ICCMIceCure Medical Ltd
12/09/202414h00PR Newswire (US)IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024NASDAQ:ICCMIceCure Medical Ltd
04/09/202414h30PR Newswire (US)IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets ConferencesNASDAQ:ICCMIceCure Medical Ltd
28/08/202414h30PR Newswire (US)USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation TechnologiesNASDAQ:ICCMIceCure Medical Ltd
20/08/202414h30PR Newswire (US)IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global MarketsNASDAQ:ICCMIceCure Medical Ltd
16/08/202414h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ICCMIceCure Medical Ltd
14/08/202414h30PR Newswire (US)IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of SurgeryNASDAQ:ICCMIceCure Medical Ltd
13/08/202414h30PR Newswire (US)IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024NASDAQ:ICCMIceCure Medical Ltd
07/08/202414h30PR Newswire (US)IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"NASDAQ:ICCMIceCure Medical Ltd
22/07/202414h30PR Newswire (US)99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer SocietyNASDAQ:ICCMIceCure Medical Ltd
19/07/202422h30PR Newswire (US)IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:ICCMIceCure Medical Ltd
09/07/202414h30PR Newswire (US)European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast CancerNASDAQ:ICCMIceCure Medical Ltd
01/07/202414h30PR Newswire (US)U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbesNASDAQ:ICCMIceCure Medical Ltd
18/06/202414h30PR Newswire (US)IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024NASDAQ:ICCMIceCure Medical Ltd
12/06/202414h30PR Newswire (US)Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionNASDAQ:ICCMIceCure Medical Ltd
 Showing the most relevant articles for your search:NASDAQ:ICCM

Dernières Valeurs Consultées

EU
VK
Vallourec
EU
GLE
Societe Generale
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
EU
SGO
Cie de SaintGobain
EU
CS
Axa
USI
USTECH100
US Tech 100
EU
PX4
SBF 120
COIN
ADAUSD
Cardano
NYSE
JPM
JP Morgan Chase
EU
VIV
Vivendi
EU
CAP
Capgemini
NASDAQ
MSFT
Microsoft
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés